Assessment of Efficacy and Safety of SPN-810 for the Treatment of Impulsive Aggression (IA) in Adolescent Subjects With Attention Deficit/Hyperactivity Disorder (ADHD) in Conjunction With Standard ADHD Treatment
Phase of Trial: Phase III
Latest Information Update: 16 Aug 2018
At a glance
- Drugs Molindone (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Registrational; Therapeutic Use
- Sponsors Supernus Pharmaceuticals
- 03 Aug 2018 Status changed from not yet recruiting to recruiting.
- 12 Jul 2018 Status changed from planning to not yet recruiting.
- 05 Mar 2018 New trial record